HORSHAM, Pa., Nov. 17, 2010 /PRNewswire/ -- Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced that Bob Radie has been appointed President and Chief Executive Officer (CEO). Thomas Beck, M.D., who was serving as interim Chief Executive Officer, will resume his role as Chief Medical Officer of the company.
Topaz Pharmaceuticals' lead product, ivermectin topical cream, is concluding Phase 3 clinical trials to support a new drug application for the treatment of head lice.
"Bob's appointment follows a comprehensive selection process by the Board of Directors to identify the best leader to take Topaz Pharmaceuticals forward and maximize the value of its lead product, a novel formulation of ivermectin," said Robert D. Casale, non-executive Chairman of the Board. "Bob's combination of business development experience as well as his expertise in successfully introducing new medicines into the commercial market is a great fit for Topaz as we prepare to report Phase 3 data on ivermectin topical cream for the treatment of head lice. Bob's extensive pharmaceutical experience should prove highly beneficial to Topaz as the company continues to advance this novel product through the drug approval process."
Mr. Radie has over 25 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as President and CEO of TransMolecular, Inc., a biotechnology company developing novel cancer diagnostic and treatment products. He previously served as Chief Business Officer at Prestwick Pharmaceuticals, Inc. and Morphotek. He played leading roles in the acquisition of Prestwick by Biovail Corp. in 2008 and Morphotek by Eisai, Inc. in 2007. He has also served as senior vice president of strategic projects and planning at Vicuron Pharmaceuticals (acquired in 2005 by Pfizer). Before joining Vicuron, Mr. Radie worked for Eli Lilly and Company,